It is my great pleasure and honor to welcome you all to the Joint Annual Conference of Medicines for Europe and IGBA here in Athens under the title Goal 2030: Access For All...
On 7 July 2021, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a (virtual) workshop titled ‘Enabling Manufacturing Capacity in the COVID-19 Pandemic’ with representatives from the leading association bodies representing biotech firms, developing and industrialized countries vaccine manufacturers, as well as innovative biopharmaceutical, generic and biosimilar companies.
Today the International Generic and Biosimilar Medicines Association (IGBA) is launching a whitepaper: A Vision for the Global Generic and Biosimilar Medicines Industry, which covers the strong contribution of this pharmaceutical sector to global health outcomes and economies, the opportunities, challenges and disruptions for the industry, its 2030 vision as well as actions needed to achieve this vision.
- IGBA Applauds UK MHRA Biosimilar Guidance Revision: Science-driven Evolution for Sustainable Access to Biologics (May 2021)
- The WHO Global Diabetes Compact: an opportunity for lasting change (April 2021)
- Sudarshan Jain takes over the position of IGBA Chair (January 2021)
- IGBA Launches First Global Biosimilars Week (November 2020)